Kimia Biosciences Limited has announced that its board meeting is scheduled to be held on Friday, May 29, 2026. The meeting has been convened in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Meeting

The primary agenda for the board meeting is to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The approval will include the standalone financial results along with the accompanying audit report.

Trading Window Closure

In continuation of an earlier intimation dated March 25, 2026, the company has informed that the trading window remains closed. This closure, effective from April 1, 2026, is in line with the company's Code of Conduct to regulate, monitor, and report trading by insiders for the prevention of insider trading. The window will continue to remain closed until 48 hours after the declaration of the aforementioned financial results.

Key Details

The information regarding the financial results will be made available on the company's official website.

Kimia biosciences Limited has filed its quarterly compliance certificate with BSE Limited, confirming adherence to SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 15, 2026.

Regulatory Compliance Submission

The compliance certificate was issued by Beetal Financial & Computer Services Private Limited, which serves as the company's Registrar and Share Transfer Agent (RTA). Company Secretary and Compliance Officer Abhishek K. Pandey submitted the documentation to BSE Limited, referencing the company's scrip code 530313.

RTA Confirmation Details

Beetal Financial & Computer Services Private Limited, a SEBI-approved Category I Registrar and Share Transfer Agent, provided comprehensive confirmation of compliance with dematerialization requirements. The RTA confirmed that securities received from Depository Participants during the quarter ended March 2026 were properly processed and confirmed to the depositories.

Compliance Verification

The certificate confirms several key compliance aspects:

• Securities received for dematerialization were accepted or rejected appropriately
• All securities have been listed on stock exchanges where previously issued securities are traded
• Security certificates received for dematerialization were mutilated and cancelled after verification
• Depository names were substituted in the register of members as registered owners within the mandated 15-day period

Corporate Structure

Kimia Biosciences Limited operates from its registered office and works at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana. The company maintains its corporate office at Aggarwal Millennium Tower-II, Netaji Subhash Place, Pitampura, New Delhi. This regulatory filing demonstrates the company's commitment to maintaining compliance with SEBI depositories and participants regulations.